Does DEFIBROTIDE Cause Thrombotic microangiopathy? 53 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 53 reports of Thrombotic microangiopathy have been filed in association with DEFIBROTIDE (DEFITELIO). This represents 1.4% of all adverse event reports for DEFIBROTIDE.
53
Reports of Thrombotic microangiopathy with DEFIBROTIDE
1.4%
of all DEFIBROTIDE reports
27
Deaths
23
Hospitalizations
How Dangerous Is Thrombotic microangiopathy From DEFIBROTIDE?
Of the 53 reports, 27 (50.9%) resulted in death, 23 (43.4%) required hospitalization, and 5 (9.4%) were considered life-threatening.
Is Thrombotic microangiopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DEFIBROTIDE. However, 53 reports have been filed with the FAERS database.
What Other Side Effects Does DEFIBROTIDE Cause?
Off label use (1,323)
Venoocclusive disease (576)
Death (463)
Multiple organ dysfunction syndrome (372)
Venoocclusive liver disease (355)
Intentional product use issue (201)
Hypotension (169)
Haemorrhage (156)
Sepsis (143)
Acute graft versus host disease (140)
What Other Drugs Cause Thrombotic microangiopathy?
TACROLIMUS (1,982)
MYCOPHENOLATE MOFETIL (820)
CYCLOSPORINE (724)
GEMCITABINE (648)
ECULIZUMAB (636)
CYCLOPHOSPHAMIDE (602)
FLUDARABINE (480)
METHOTREXATE (447)
CARFILZOMIB (350)
METHYLPREDNISOLONE (345)
Which DEFIBROTIDE Alternatives Have Lower Thrombotic microangiopathy Risk?
DEFIBROTIDE vs DEFLAZACORT
DEFIBROTIDE vs DEGARELIX
DEFIBROTIDE vs DELAFLOXACIN MEGLUMINE
DEFIBROTIDE vs DELAMANID
DEFIBROTIDE vs DELANDISTROGENE MOXEPARVOVEC-ROKL